ADC Linker

DMAC-SPDB-sulfo is a cleavable linker specifically designed for use in the synthesis of antibody-drug conjugates (ADCs). This sulfo-based compound facilitates the controlled release of therapeutic agents upon cellular internalization, allowing for targeted delivery and enhanced efficacy. Researchers can utilize DMAC-SPDB-sulfo in the development of ADCs to improve treatment precision in various cancer therapies, aiding in the advancement of targeted drug delivery systems.

cBu-Cit-OH is a cyclic alkene-based linker designed for antibody-drug conjugate (ADC) applications. This reagent facilitates the stable attachment of cytotoxic agents to antibodies, enhancing targeted delivery and efficacy in cancer therapeutics. Its unique structural properties enable effective conjugation, making it suitable for the synthesis and development of innovative ADCs in research settings.

Ald-Ph-amido-C2-nitrate is a non-cleavable ADC linker designed for antibody-drug conjugates (ADCs). This compound facilitates stable attachment between antibodies and cytotoxic agents, enhancing the efficacy of targeted cancer therapies. Its unique thiazolidine structure provides robust performance in the development of innovative therapeutic strategies.

Bis-PEG2-PFP ester is a non-cleavable linker that comprises two units of polyethylene glycol (PEG) and is essential for the synthesis of antibody-drug conjugates (ADCs). Its unique structure makes it suitable for use in peptide-based PROTACs (Proteolysis Targeting Chimeras), facilitating targeted degradation of specific proteins. This reagent supports advanced research in the fields of targeted therapy and protein regulation.

Mal-amido-PEG3-C1-NHS ester is a non-cleavable 3-unit polyethylene glycol (PEG) linker designed for antibody-drug conjugate (ADC) synthesis. This reactive NHS ester facilitates the conjugation of cytotoxic agents to antibodies, enabling targeted delivery for enhanced therapeutic efficacy. Its application is crucial in the development of ADCs aimed at improving treatment outcomes in various cancers.

Fmoc-Ala-Ala-Ala-amide-C-O-C-COOH functions as a cleavable linker for antibody-drug conjugates (ADCs). This compound enables the selective release of cytotoxic drugs upon internalization by target cells, enhancing the efficacy and specificity of cancer therapies. It is widely used in the development of ADCs for various research applications, including targeted delivery and controlled drug release studies.

MC-Val-Cit-PAB-NH-C2-NH-Boc is a cathepsin-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates targeted delivery of cytotoxic agents by enabling selective release upon cleavage in the tumor microenvironment. Its application in ADC development supports research in cancer therapeutics and targeted drug delivery mechanisms.

Ald-Ph-amido-PEG3-NHS ester is a non-cleavable three-unit polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the stable attachment of cytotoxic agents to antibodies, thereby enhancing targeted delivery and minimizing systemic toxicity. It is essential for researchers developing ADCs aimed at improving therapeutic efficacy in cancer treatment and other diseases.

Sulfo-SIAB sodium is a non-cleavable monovalent bilinker designed for antibody-drug conjugate (ADC) applications. This linker facilitates the stable attachment of drugs to antibodies, ensuring enhanced therapeutic efficacy and reduced off-target effects. It is particularly useful in the development of ADCs for targeted cancer therapies and other biopharmaceuticals that require precise delivery of active compounds.

Fmoc-Phe-Lys(Trt)-PAB is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the selective delivery of therapeutic agents to targeted cells, enhancing the efficacy and minimizing off-target effects of the treatment. Its unique structure allows for the release of the drug upon cleavage, making it an essential component in the development of ADCs for cancer therapy and other applications in targeted treatment strategies.

m-PEG9-Amine is a polyethylene glycol (PEG)-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker facilitates the attachment of biomolecules, enabling targeted protein degradation and precise delivery of therapeutic agents. m-PEG9-Amine is essential for advancing research in targeted therapy and bioconjugation applications.

Mal-PEG4-VA is a cleavable ADC linker featuring a Maleimide moiety, which enables the selective conjugation of drugs to antibodies. This compound is primarily utilized in the synthesis of antibody-drug conjugates (ADCs), facilitating targeted therapeutic strategies in cancer treatment. Its ability to release the drug in response to specific stimuli enhances the therapeutic efficacy of ADCs while minimizing off-target effects.

Fmoc-Ala-Ala-Asn(Trt)-OH is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the selective attachment of cytotoxic agents to antibodies, enabling targeted delivery and enhanced therapeutic efficacy. Its application in ADC development supports research in cancer therapeutics and personalized medicine.

Bis-PEG17-NHS ester is a PEG-based linker designed for efficient conjugation in both PROTAC and antibody-drug conjugate (ADC) synthesis. Its NHS ester functionality allows for selective coupling to amine-containing molecules, facilitating the development of targeted therapies. This reagent is particularly useful in the development of PROTACs for targeted protein degradation and in the construction of ADCs that deliver cytotoxic agents to specific cancer cells.

Phe-Lys(Trt)-PAB is a peptide-based linker designed for use in antibody-drug conjugates (ADCs), featuring a cleavable bond for targeted drug release. This cathepsin-sensitive linker enhances the stability and efficacy of ADCs by facilitating payload release in the tumor microenvironment. It is suitable for research applications involving ADC development and optimization.

PAB-Ala-Val-CO-C2-mal is a cleavable antibody-drug conjugate (ADC) linker designed for the synthesis of targeted therapeutics. By facilitating the selective release of cytotoxic agents upon internalization, this linker enhances the efficacy of ADCs while minimizing off-target effects. Its application is pivotal in developing innovative cancer treatments through precise delivery mechanisms.

NMS-P945 is a reactive linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the conjugation to monoclonal antibodies (mAbs) with a reproducible Drug Antibody Ratio (DAR) exceeding 3.5. This compound enhances the efficacy and stability of ADCs, making it a valuable tool in targeted cancer therapy research applications.

NHPI-PEG3-C2-Pfp ester is a non-cleavable linker composed of a three-unit polyethylene glycol (PEG) chain designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the stable attachment of drug molecules to antibodies, enhancing therapeutic efficacy while minimizing off-target effects. Its unique structure allows for improved solubility and biocompatibility, making it suitable for various applications in drug development and cancer therapeutics.

Propargyl-PEG4-CH2CH2-Boc is a non-cleavable ADC linker designed for the synthesis of antibody-drug conjugates (ADCs) targeting Galectin-3. This versatile linker incorporates PEG and an alkyl/ether moiety, making it suitable for the development of PROTACs (PROteolysis TArgeting Chimeras). As a click chemistry reagent, it features an alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing compounds, enhancing the efficacy of bioconjugation processes in chemical biology research.

SPDP-sulfo is a cleavable ADC linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates targeted drug delivery by linking cytotoxic agents to antibodies, ensuring selective action against specific tumor cells. Its ability to undergo cleavage in the reducing environment of the target cells makes it suitable for applications in cancer research and therapeutic development.

EGGGG-PEG8-amide-bis(deoxyglucitol) is a cleavable linker designed for antibody-drug conjugates (ADCs). This reagent facilitates targeted delivery of cytotoxic agents to specific cells, enhancing therapeutic efficacy while minimizing off-target effects. It is suitable for research involving ADC development and optimization in cancer therapy.

N-Boc-PEG9-alcohol is a polyethylene glycol (PEG)-based linker utilized in the synthesis of antibody-drug conjugates (ADCs) and PROTACs. This cleavable linker facilitates the conjugation of bioactive molecules, enhancing the pharmacokinetic properties of ADCs. Its application extends to the development of targeted degraders, making it a valuable tool in chemical biology and drug discovery research.

Ald-CH2-PEG5-azide is a non-cleavable linker consisting of a five-unit polyethylene glycol (PEG) chain, specifically designed for use in antibody-drug conjugates (ADCs). This compound incorporates an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules and those containing DBCO or BCN groups. Its versatile reactivity makes it a valuable tool for the efficient synthesis of ADCs, facilitating targeted drug delivery in research applications.

Azide-C2-Azide is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). Functioning through click chemistry, it features an azide group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with compounds possessing alkyne functionalities. Additionally, Azide-C2-Azide is capable of undergoing strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN-containing molecules, making it a versatile tool in chemical biology and drug development applications.

SC-Val-Cit-PAB is a cleavable linker designed for antibody-drug conjugates (ADCs), facilitating targeted delivery of cytotoxic agents to cancer cells. It undergoes enzymatic cleavage, releasing the drug within the tumor microenvironment, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. This reagent is essential for research in developing innovative ADC formulations for cancer treatment.

MC-Gly-Gly-Phe-Gly-cyclopropylacetic acid is a cleavable linker specifically designed for the assembly of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic agents to antibodies, enabling targeted delivery and enhanced therapeutic efficacy. Its unique structure allows for selective cleavage under physiological conditions, resulting in the release of the drug at the desired site of action. This makes it a valuable tool in the development of innovative cancer therapies.

N-Fmoc-EvcPAB-PNP is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the controlled release of therapeutic agents upon internalization by target cells, enhancing the targeted delivery of cytotoxic drugs. This compound is essential for research applications involving ADC development and optimization, allowing for the study of efficacy and pharmacokinetics in targeted cancer therapies.

NHPI-PEG3-C2-NHS ester is a non-cleavable three-unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This linker enhances the solubility and stability of ADCs while maintaining their potency. It is particularly useful for facilitating the targeted delivery of cytotoxic agents to cancer cells, making it a valuable tool in cancer research and development of therapeutic strategies.

Fmoc-MeVal-OSu is a specialized linker utilized in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of therapeutic agents to antibodies, enhancing targeted delivery and efficacy in cancer therapies. Fmoc-MeVal-OSu is instrumental in research applications focused on developing novel ADCs for improved treatment outcomes in oncology.

PC-Biotin-PEG4-PEG3-azide is an advanced cleavable linker designed for antibody-drug conjugate (ADC) applications. This reagent features an azide functional group, enabling participation in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules possessing DBCO or BCN groups, making it a versatile tool in the creation of targeted therapeutics.

Hydroxy-PEG10-acid is a PEG-based non-cleavable linker designed for the synthesis of Antibody-Drug Conjugates (ADCs). Its primary mechanism involves the formation of stable covalent bonds facilitating the attachment of cytotoxic agents to antibodies. This linker enhances the therapeutic efficacy of ADCs by improving solubility and distribution while minimizing systemic toxicity. It finds application in drug development aimed at targeted cancer therapies and other diseases requiring precise delivery systems.

Me-Tet-PEG8-NHBoc is an ADC linker designed for targeted drug delivery applications. This compound features an 8-unit polyethylene glycol (PEG) chain and a tetrazine moiety, enabling it to undergo inverse electron demand Diels-Alder (iEDDA) reactions with trans-cyclooctenes (TCO). Its unique properties make it suitable for use in antibody-drug conjugates (ADCs), facilitating the precise attachment of therapeutic agents to antibodies while enhancing solubility and stability.

Me-Tet-PEG5-NHS is an ADC linker designed to facilitate site-specific conjugation through its Tetrazine moiety. This compound can engage in a selective inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) derivatives, enabling the formation of stable linkages in antibody-drug conjugates (ADCs). Its five PEG units enhance solubility and promote improved pharmacokinetics, making it suitable for targeted drug delivery applications in cancer research and therapeutic development.

N-Succinimidyl 3-(Bromoacetamido)propionate is a versatile PEG-based linker designed for PROTAC (proteolysis-targeting chimeras) synthesis. This compound facilitates the effective conjugation of small molecules to target proteins, enabling targeted protein degradation. Additionally, it serves as a cleavable linker for the development of antibody-drug conjugates (ADCs), enhancing therapeutic efficacy in cancer research. This reagent is essential for studies focused on protein modulation and targeted therapies.

4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of therapeutic agents to antibodies, promoting targeted delivery and enhanced efficacy in cancer treatment. Its unique disulfide bond allows for selective cleavage within the tumor environment, releasing the cytotoxic drug while minimizing systemic toxicity.

MDTF free acid serves as a non-cleavable linker in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates stable attachment of cytotoxic drugs to antibodies, enhancing targeted delivery to cancer cells while minimizing systemic toxicity. Its application is crucial in the development of effective ADCs for therapeutic research in oncology.

Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc is an innovative ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of active molecules to antibodies, enhancing targeted delivery in therapeutic applications. Its unique chemical structure allows for efficient linkage, making it an essential tool for researchers in drug development focused on precision oncology and targeted therapies.

Hydroxy-PEG3-SS-PEG3-alcohol is a cleavable six-unit polyethylene glycol (PEG) linker designed for applications in antibody-drug conjugate (ADC) synthesis. This compound facilitates the targeted delivery of cytotoxic agents to specific cells by enabling the selective release of the drug upon cellular uptake. Its functionalized structure supports the development of effective and precise biologic therapies within cancer research and drug development.

Me-Tet-PEG4-NH2 is an ADC linker featuring a tetracine group and four polyethylene glycol (PEG) units. This compound facilitates targeted drug delivery through a specific inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctenes (TCOs). Its design enhances the stability and solubility of antibody-drug conjugates, making it a valuable tool for therapeutic applications in targeted cancer treatments and other biomedical research.

DBCO-NHCO-PEG4-acid is a PEG-based linker designed for application in antibody-drug conjugates (ADCs) and PROTAC synthesis. This linker features a DBCO group that participates in strain-promoted alkyne-azide cycloaddition (SPAAC), facilitating selective conjugation with azide-containing molecules. Its chemical properties make it ideal for developing targeted therapeutics that can modulate protein levels in biological research, enhancing experimental outcomes in drug discovery and development.

Glu(OtBu)-Val-Cit-PAB-OH is a non-cleavable ADC linker designed for use in antibody-drug conjugates. This compound facilitates the synthesis of protein-tubulysin conjugates, enabling targeted delivery of cytotoxic agents. Its stability under physiological conditions makes it suitable for various cancer research applications and the development of novel therapeutic strategies.

5-Hydroxypentanoic acid serves as a versatile PROTAC linker, playing a crucial role in targeted protein degradation technology. This compound facilitates the synthesis of PROTAC AR-V7 degrader-1, contributing to innovative research in protein regulation and therapeutic development. Its structural characteristics enhance the design of bifunctional molecules for selective protein degradation, making it a valuable reagent in life sciences research.

Amino-PEG10-OH is a non-cleavable, 10-unit polyethylene glycol (PEG) linker primarily utilized in the development of antibody-drug conjugates (ADCs). This versatile linker also serves a critical role in the synthesis of proteolysis-targeting chimeras (PROTACs). Its hydrophilic properties enhance solubility and stability, making it suitable for diverse applications in chemical biology and therapeutic development.

NO2-SPDMV is a cleavable linker designed for use in antibody-drug conjugates (ADCs). It facilitates the targeted delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing systemic exposure. This linker is essential for research applications focused on ADC development and optimization.

Mal-Ala-Ala-PAB-PNP is a cleavable linker designed for use in the development of antibody-drug conjugates (ADCs). This compound is engineered to facilitate the selective release of therapeutic agents upon internalization by target cells, enhancing the efficacy of targeted cancer therapies. Its application in ADC synthesis supports the study of targeted delivery mechanisms and the optimization of therapeutic strategies in oncology research.

Me-Tet-PEG5-COOH is an ADC linker designed to facilitate targeted drug delivery through the incorporation of a tetrazine moiety. This compound exhibits high reactivity in inverse electron demand Diels-Alder (iEDDA) reactions with trans-cyclooctene (TCO) derivatives, enabling precise conjugation to therapeutic agents. Its unique structure enhances stability and solubility, making it suitable for applications in antibody-drug conjugate (ADC) development and bioconjugation research.

Gly-amide-OMe-Cbz serves as an ADC linker, facilitating the synthesis of antibody-drug conjugates (ADCs). This compound enables the efficient conjugation of active molecules to antibodies, supporting targeted delivery in therapeutic applications. Its structural features make it a valuable reagent for researchers engaged in the development of innovative ADCs in cancer therapy and other applications.

N-Methyl-N-[(3-methyldithio)-1-oxopropyl]-L-alanine is a specialized linker designed for use in antibody-drug conjugates (ADCs). This compound effectively facilitates the attachment of cytotoxic agents to monoclonal antibodies, enhancing the therapeutic efficacy of targeted cancer treatments. Its unique structure allows for improved stability and release profiles in biological systems, making it a valuable tool for research applications focused on ADC development and optimization.

Benzyl N1-[PEG1-NHS]-N6-(t-Boc)-L-lysinate is an advanced ADC linker designed for effective bioconjugation applications. Its structure features a benzyl group, a PEG unit, an NHS ester, and a t-Boc-protected L-lysine, facilitating the attachment of therapeutic agents to antibodies. This reagent is ideal for research focused on antibody-drug conjugate technology and chemical modifications in various biochemical studies.

Fmoc-Ala-Ala-Pro-OH is a Fmoc-protected tripeptide linker that serves as a crucial component in the development of antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of cytotoxic agents to antibodies, enhancing targeted delivery and therapeutic efficacy. Its unique structure provides stability and reliable linkages, making it an essential tool for research in targeted cancer therapies and other biomedical applications.